Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Diagnostic & Testing Substances
- Sub-Industry: N/A
- Symbol: NASDAQ:BIOC
- CUSIP: N/A
- Web: www.biocept.com
Capitalization:- Market Cap: $37.51 million
- Outstanding Shares: 30,253,000
Average Prices:- 50 Day Moving Avg: $1.28
- 200 Day Moving Avg: $1.56
- 52 Week Range: $0.74 - $3.39
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.86
- P/E Growth: -0.04
Sales & Book Value:- Annual Revenue: $5.3 million
- Price / Sales: 7.02
- Book Value: $0.26 per share
- Price / Book: 4.73
Profitability:- EBIDTA: ($18,190,000.00)
- Net Margins: -359.48%
- Return on Equity: -550.35%
- Return on Assets: -175.51%
Debt:- Debt-to-Equity Ratio: 0.13%
- Current Ratio: 2.13%
- Quick Ratio: 2.02%
Misc:- Average Volume: 328,072 shs.
- Beta: 3.02
- Short Ratio: 14.97
Frequently Asked Questions for Biocept (NASDAQ:BIOC)
What is Biocept's stock symbol?
Biocept trades on the NASDAQ under the ticker symbol "BIOC."
How were Biocept's earnings last quarter?
Biocept, Inc. (NASDAQ:BIOC) released its quarterly earnings results on Thursday, August, 10th. The company reported ($0.21) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.20) by $0.01. The company earned $1.28 million during the quarter, compared to the consensus estimate of $1.23 million. Biocept had a negative net margin of 359.48% and a negative return on equity of 550.35%. View Biocept's Earnings History.
When will Biocept make its next earnings announcement?
Where is Biocept's stock going? Where will Biocept's stock price be in 2017?
3 analysts have issued twelve-month target prices for Biocept's shares. Their predictions range from $2.00 to $3.00. On average, they expect Biocept's share price to reach $2.50 in the next year. View Analyst Ratings for Biocept.
Who are some of Biocept's key competitors?
Some companies that are related to Biocept include Cardiome Pharma Corporation (CRME), Vermillion (VRML), BioLife Solutions (BLFS), CytRx Corporation (CYTR), Catasys (CATS), KalVista Pharmaceuticals (KALV), Digirad Corporation (DRAD), Sophiris Bio (SPHS), Second Sight Medical Products (EYES), Galectin Therapeutics (GALT), Applied Genetic Technologies Corporation (AGTC), PURE Bioscience (PURE), Concordia International Corp. (CXRX), Flex Pharma (FLKS), Egalet Corporation (EGLT), TRACON Pharmaceuticals (TCON), SCYNEXIS (SCYX) and Endocyte (ECYT).
Who are Biocept's key executives?
Biocept's management team includes the folowing people:
- Michael W. Nall, President, Chief Executive Officer, Director
- Timothy C. Kennedy, Chief Financial Officer and Senior Vice President of Operations
- Lyle J. Arnold Ph. D., Senior Vice President - Research & Development, Chief Scientific Officer
- Veena Singh M.D., Senior Vice President, Senior Medical Director
- Michael Terry, Senior Vice President - Commercial Operations
- Raaj Trivedi, Vice President - Commercial Operations
- David S. Moskowitz, Vice President - Strategy and Corporate Communications
- David F. Hale, Non-Executive Chairman of the Board
- Marsha A. Chandler Ph.D., Independent Director
- Bruce E. Gerhardt CPA, Independent Director
Who owns Biocept stock?
Biocept's stock is owned by many different of retail and institutional investors. Top institutional shareholders include
ALLY BRIDGE LB HEALTHCARE MASTER FUND LTD
(14.46%), Vanguard Group Inc. (2.87%) and Creative Planning (0.93%). Company insiders that own Biocept stock include Bruce Gerhardt, Claire Reiss, David F Hale, Ivor Royston, Lyle J Arnold and Timothy Kennedy. View Institutional Ownership Trends for Biocept.
Who bought Biocept stock? Who is buying Biocept stock?
Biocept's stock was acquired by a variety of institutional investors in the last quarter, including Creative Planning and Vanguard Group Inc.. Company insiders that have bought Biocept stock in the last two years include Bruce Gerhardt, Claire Reiss, David F Hale, Ivor Royston, Lyle J Arnold and Timothy Kennedy. View Insider Buying and Selling for Biocept.
How do I buy Biocept stock?
Shares of Biocept can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biocept's stock price today?
One share of Biocept stock can currently be purchased for approximately $1.23.
MarketBeat Community Rating for Biocept (NASDAQ BIOC)MarketBeat's community ratings are surveys of what our community members think about Biocept and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Biocept (NASDAQ:BIOC)Earnings History by Quarter for Biocept (NASDAQ BIOC)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/7/2017 | | | | | | | N/A |  |
| 8/10/2017 | Q2 2017 | ($0.20) | ($0.21) | $1.23 million | $1.28 million | View | N/A | |
| 3/7/2017 | Q4 2016 | ($0.34) | ($0.27) | $1.26 million | $1.29 million | View | Listen | |
| 11/9/2016 | Q316 | ($0.57) | ($0.57) | $0.76 million | $1.05 million | View | Listen | |
| 8/2/2016 | Q216 | ($0.22) | ($0.20) | $0.37 million | $0.66 million | View | N/A | |
| 5/12/2016 | Q116 | ($0.23) | ($0.25) | $0.48 million | $0.22 million | View | Listen | |
| 3/9/2016 | Q415 | ($0.26) | ($0.24) | $76.00 million | $218.00 million | View | N/A | |
| 11/5/2015 | Q315 | ($0.22) | ($0.24) | $0.78 million | $0.17 million | View | N/A | |
| 8/10/2015 | Q215 | ($0.23) | ($0.22) | $19.25 million | $76.77 million | View | Listen | |
| 5/12/2015 | Q115 | ($0.61) | ($0.37) | $0.30 million | $0.15 million | View | Listen | |
| 3/9/2015 | Q414 | ($0.88) | ($0.87) | $0.30 million | $0.08 million | View | N/A | |
| 11/13/2014 | Q3 2014 | ($0.82) | ($0.87) | $0.40 million | $0.01 million | View | N/A | |
| 8/14/2014 | Q2 2014 | ($0.67) | ($0.67) | $0.10 million | $0.02 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Biocept (NASDAQ:BIOC)2017 EPS Consensus Estimate: ($0.79)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.22) | ($0.19) | ($0.21) |
| Q2 2017 | 2 | ($0.21) | ($0.19) | ($0.20) |
| Q3 2017 | 2 | ($0.21) | ($0.17) | ($0.19) |
| Q4 2017 | 2 | ($0.20) | ($0.18) | ($0.19) |
(Data provided by Zacks Investment Research)
Dividend History for Biocept (NASDAQ:BIOC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Biocept (NASDAQ:BIOC)Insider Ownership Percentage: 7.70%
Institutional Ownership Percentage: 6.92%
Insider Trades by Quarter for Biocept (NASDAQ:BIOC)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 10/19/2016 | Claire Reiss | Major Shareholder | Buy | 227,272 | $1.10 | $249,999.20 | |
| 10/19/2016 | David F. Hale | Director | Buy | 90,909 | $1.10 | $99,999.90 | |
| 10/19/2016 | Lyle J. Arnold | SVP | Buy | 45,000 | $1.10 | $49,500.00 | |
| 10/19/2016 | Timothy Kennedy | CFO | Buy | 36,363 | $1.10 | $39,999.30 | |
| 5/4/2016 | Bruce Gerhardt | Director | Buy | 25,000 | $1.00 | $25,000.00 | |
| 5/4/2016 | Claire Reiss | Major Shareholder | Buy | 614,273 | $1.00 | $614,273.00 | |
| 2/13/2015 | David F Hale | Chairman | Buy | 40,000 | $1.25 | $50,000.00 | |
| 2/13/2015 | Marsha Alpert Chandler | Director | Buy | 2,000 | $1.25 | $2,500.00 | |
| 2/13/2015 | Michael W Nall | CEO | Buy | 12,000 | $1.25 | $15,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Biocept (NASDAQ:BIOC)
Latest Headlines for Biocept (NASDAQ:BIOC)
| Source: |
|
| Date | Headline |
|---|
 | 5 Medtech Stocks to Steer Clear of Amid Political Chaos - Nasdaq
www.nasdaq.com - September 20 at 2:33 AM |
 | 5 Medtech Stocks to Steer Clear of Amid Political Chaos
finance.yahoo.com - September 19 at 4:31 PM |
 | Biocept, Inc. (BIOC) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - September 17 at 2:50 AM |
| Analysts Anticipate Biocept, Inc. (BIOC) Will Announce Quarterly Sales of $1.40 Million
www.americanbankingnews.com - September 9 at 8:22 AM |
| Biocept Launches Liquid Biopsy Test for NRAS Mutations
finance.yahoo.com - September 5 at 6:10 PM |
| Biocept, Inc. (BIOC) Downgraded to Strong Sell at ValuEngine
www.americanbankingnews.com - September 3 at 9:00 PM |
| Biocept to Present at the 6th Annual Gateway Conference on September 6, 2017 in San Francisco
finance.yahoo.com - August 28 at 4:33 PM |
| Biocept to Present at the 6th Annual Gateway Conference on September 6, 2017 in San Francisco
finance.yahoo.com - August 28 at 4:33 PM |
| Biocept, Inc. (BIOC) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - August 23 at 3:32 AM |
| Biocept, Inc. (BIOC) Expected to Post Quarterly Sales of $1.40 Million
www.americanbankingnews.com - August 21 at 5:06 AM |
 | BRIEF-Biocept Inc files for disposition of up to 2.9 million shares of common stock
www.reuters.com - August 18 at 9:38 PM |
 | Biocept and UT Southwestern Medical Center Announce Clinical Study to Profile and Monitor Non-Small Cell Lung ... - PR Newswire (press release)
www.prnewswire.com - August 17 at 10:57 PM |
| BRIEF-Biocept, UT Southwestern Medical Center announce clinical study to profile, monitor non-small cell lung cancer patients
www.reuters.com - August 17 at 5:55 PM |
| Biocept and UT Southwestern Medical Center Announce Clinical Study to Profile and Monitor Non-Small Cell Lung Cancer Patients with ALK Rearrangements
finance.yahoo.com - August 17 at 5:55 PM |
| Zacks Investment Research Downgrades Biocept, Inc. (BIOC) to Sell
www.americanbankingnews.com - August 16 at 5:04 PM |
| BRIEF-Biocept enters into distribution agreement with Global Laboratory Product Supplier VWR
www.reuters.com - August 14 at 9:59 PM |
| BRIEF-Biocept enters into distribution agreement with Global Laboratory Product Supplier VWR - Reuters
www.reuters.com - August 14 at 4:57 PM |
| Biocept Enters Into Exclusive Distribution Agreement with Global Laboratory Product Supplier VWR
finance.yahoo.com - August 14 at 4:57 PM |
| Biocept, Inc. (BIOC) Issues Quarterly Earnings Results
www.americanbankingnews.com - August 11 at 6:02 PM |
 | Biocept's (BIOC) CEO Michael Nall on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 11 at 3:48 AM |
| Biocept Announces Private Placement of $2.2 Million of Common Stock with Ally Bridge LB Healthcare Master Fund
finance.yahoo.com - August 10 at 5:41 PM |
| Biocept Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 10 at 5:41 PM |
| BRIEF-Biocept executes preferred provider agreement with Scripps Health Plan
www.reuters.com - August 8 at 9:24 PM |
| Health Care Sector Update for 08/07/2017: BIOC - Nasdaq
www.nasdaq.com - August 7 at 10:05 PM |
| Biocept Executes Preferred Provider Agreement with Scripps Health Plan Expanding Patient Coverage for its Liquid Biopsy Platform
finance.yahoo.com - August 7 at 5:04 PM |
| Critical Analysis: Biocept (BIOC) & Natera (NTRA)
www.americanbankingnews.com - August 4 at 7:42 AM |
| ETFs with exposure to Biocept, Inc. : August 3, 2017
finance.yahoo.com - August 3 at 11:03 PM |
| Comparing TrovaGene (TROV) and Biocept (NASDAQ:BIOC)
www.americanbankingnews.com - August 3 at 8:48 PM |
| Biocept, Inc. (NASDAQ:BIOC) to Release Earnings on Thursday
www.americanbankingnews.com - August 3 at 8:10 PM |
| Biocept to Release Second Quarter 2017 Financial Results and ... - PR Newswire (press release)
www.prnewswire.com - August 3 at 6:00 PM |
| Biocept to Release Second Quarter 2017 Financial Results and Host Investor Conference Call on August 10, 2017
finance.yahoo.com - August 3 at 6:00 PM |
| Analyzing Biocept (NASDAQ:BIOC) & NanoString Technologies (NSTG)
www.americanbankingnews.com - August 1 at 10:26 PM |
| Biocept (BIOC) vs. TrovaGene (TROV) Head to Head Survey
www.americanbankingnews.com - July 30 at 6:25 PM |
| Biocept, Inc. (NASDAQ:BIOC) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - July 29 at 7:27 AM |
| Global stocks rise on corporate earnings, ahead of Fed
finance.yahoo.com - July 26 at 5:08 PM |
| Biocept, Inc. (NASDAQ:BIOC) Set to Announce Earnings on Monday
www.americanbankingnews.com - July 24 at 8:04 AM |
| Reviewing Biocept (NASDAQ:BIOC) and NanoString Technologies (NSTG)
www.americanbankingnews.com - July 20 at 6:27 PM |
| Financial Contrast: NanoString Technologies (NSTG) and Biocept (BIOC)
www.americanbankingnews.com - July 19 at 4:12 PM |
| Featured Company News - Biocept Commercially Launches Progesterone Receptor Liquid Biopsy Test
finance.yahoo.com - July 17 at 4:51 PM |
| Financial Analysis: Biocept (BIOC) versus Quotient Limited (QTNT)
www.americanbankingnews.com - July 16 at 10:28 PM |
| Biocept Expands Commercial Offering of Clinically Actionable Biomarker Assays with Launch of Liquid Biopsy Test for ... - PR Newswire (press release)
www.prnewswire.com - July 14 at 11:33 PM |
| ETF Preview: ETFs, Stocks Point to Higher Open as Wall Street Mulls Earnings from Banks, Retail Sales and Inflation Data
www.nasdaq.com - July 14 at 6:29 PM |
| BRIEF-Biocept launches liquid biopsy test for progesterone receptor detection
www.reuters.com - July 14 at 6:29 PM |
| Biocept Expands Commercial Offering of Clinically Actionable Biomarker Assays with Launch of Liquid Biopsy Test for Progesterone Receptor Detection
finance.yahoo.com - July 14 at 6:29 PM |
 | Global Circulating Tumor Cell (CTC) Diagnostics - Biotechnology
www.bizjournals.com - July 13 at 1:42 AM |
| ETFs with exposure to Biocept, Inc. : July 12, 2017
finance.yahoo.com - July 12 at 5:05 PM |
| FDA advisers endorse what could be 1st US gene therapy
finance.yahoo.com - July 12 at 5:05 PM |
| Zacks Investment Research Downgrades Biocept, Inc. (BIOC) to Hold
www.americanbankingnews.com - July 12 at 4:46 PM |
| Biocept, Inc. (BIOC) Lifted to "Sell" at ValuEngine
www.americanbankingnews.com - July 9 at 12:02 AM |
| Biocept, Inc. (BIOC) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - July 4 at 10:02 AM |
Biocept (BIOC) Chart for Tuesday, September, 26, 2017
